Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 15-95 

High dose EC x 3 supported by PBSC vs. EC/AC x 4 followed by CMF as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (less than 65 years) patients

DESIGN

Design Trial 15-95

Results & Publications


Presentations


Publications

Study Chairs
Dr. Russel Basser - Melbourne, Australia
Prof. Monica Castiglione - Bern, Switzerland

Statistician
Anne O'Neill

Trial Coordinators
Joie Celano, Meghan Metz, Kris Rickard, Tara Scolese
IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg10-15@fstrf.org

Date of Activation
July 1995

Date of Closure
March 15, 2000

Targeted Accrual
300 patients

Final Accrual
344 patients


Results Publications Results & Publications
Other Pathology


News

11.12.2008:
BIG 1-98: Results from sequential treatment analysis and updated monotherapy analysis

11.12.2008:
Brinker Award for Richard Gelber and Aron Goldhirsch

11.12.2008:
All presentations from investigators' meetings at San Antonio Breast Cancer Symposium now

All News

 
  Print